STRUCTURE THERAPEUTICS INC (GPCR) Stock News
NASDAQ:GPCR - Nasdaq - US86366E1064 - ADR - Currency: USD
GPCR Latest News, Press Relases and Analysis
Why Structure Therapeutics Stock Was Stumbling This Week
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing...
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of...
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs space continues to heat up. Here's the latest news from the segment.
Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing...
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be...
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2...
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing...
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
The analyst is closely watching MariTide, a potential monthly injection to treat obesity.
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
The company is working on a drug that mimics apelin, which is released following exercise.
Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer
SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company...
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
The major indexes reclaimed key levels and many leaders flashed buy signals.
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.
Structure Therapeutics Appoints Angus C. Russell to Board of Directors
Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry...
Structure Therapeutics Appoints Angus C. Russell to Board of Directors
Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing...
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.